Changes in Beneficial Ownership · 4
Artelo Biosciences, Inc.
ARTLNASDAQEQUITYCurrent
Changes in Beneficial Ownership
Structured filing — 4
form4.xml
Filing details
- Report period
- 2026-07-17-05:00
- Issuer
- ARTELO BIOSCIENCES, INC.
- Issuer CIK
- 0001621221
- Trading symbol
- ARTL
Reporting owner 1
- Name
- Reyes Gregory
- Reporting owner CIK
- 0001404055
- Relationship
- Director
- Address
- C/O ARTELO BIOSCIENCES, INC., 505 LOMAS SANTA FE, SUITE 160, SOLANA BEACH, CA, 92075
Derivative transactions
| Security | Conversion / exercise price (USD) | Transaction date | Code | Amount | A / D | Price (USD) | Exercisable | Expires | Underlying security | Underlying shares | Owned after | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy) | 1.15 | 2026-07-17-05:00 | A · Form 4 | 136 | A | 0.00 | [F1] | 2036-07-17 | Common Stock | 136 | 136 | D |
Table key
- A · Form 4
- Acquisition by grant, award or otherwise under Rule 16b-3(d)
- A
- Acquired
- D
- Direct
Footnotes
- F1
- Subject to the Reporting Person continuing to be a Service Provider (as such term is defined in the Issuer's Plan) through each such applicable vesting date, one hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) the one (1) year anniversary of the Vesting Commencement Date, or (ii) the day prior to the date of the annual meeting of the Issuer's stockholders next following the Vesting Commencement Date. "Vesting Commencement Date" shall mean July 17, 2026.↩ 1
Signature 1
- Signed
- /s/ Gregory D. Gorgas, as Attorney-in-Fact
- Date
- 2026-07-21
Filed exhibits
- POWER OF ATTORNEY ↗artl_ex24.htm
Company context
We are currently developing a novel, benzimidazole dual cannabinoid (CB) agonist that targets both the CB1 and CB2 peripheral receptors. This synthetic small molecule program is a G protein-coupled receptor (“GPCR”) designated ART27.13 and was initially developed by AstraZeneca plc. We are developing ART27.13 as a potential treatment for cancer-related anorexia and it is currently in a Phase 1b/2a trial, titled the Cancer Appetite Recovery Study (“CAReS”). In an interim analysis of the on-going Phase 2a CAReS trial, patients with cancer anorexia receiving ART27.13 demonstrated a mean weight gain of over 6% compared to a 5% loss in the placebo group, while maintaining a safety profile similar to the Phase 1b despite doses up to twice the previous maximum. Currently there is no FDA approved treatment for cancer anorexia cachexia syndrome.